With approval for new drug, Alexion aims to switch patients from Soliris
Justice Department alleges more drug copay kickbacks
The Innovative Medicines Fund: A catalyst to drive access to rare disease treatments? September 2021
Eculizumab - Wikipedia
Alexion to begin Phase 3 testing on drug to treat ALS
Alexion trials rare disease drug Ultomiris in severe COVID-19 cases | Pharmaphorum
Alexion crowns myasthenia gravis as its best Soliris launch ever | Fierce Pharma
Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics™ for Rare Diseases | Business Wire
NICE rejects second Alexion ultra-rare disease drug | Pharmaphorum
AstraZeneca acquires US drug developer Alexion in massive $39 billion deal | International Business
Alexion's Soliris wins FDA 'orphan' nod | Hartford Business Journal
Alexion Pharma's Bloated Blockbuster Deal Still Haunts - TheStreet
Alexion Pharmaceuticals - Drug Discovery and Development
AstraZeneca to Acquire Alexion for $39B, Adding Rare Disease, Immunology Assets
New Alexion rare-disease drug wins FDA approval | New Haven BIZ
Canadian Drug Watchdog Orders Alexion to Lower Price of Soliris, Refund Overcharges - Global Genes
Five years later, Alexion sets aside $25M to resolve SEC's foreign bribery probe | Fierce Pharma
Alexion Pharmaceuticals Marketed Drugs - GlobalData
Alexion Says FDA Grants Orphan Drug Designation To ALXN1210 | World Pharma Today
AstraZeneca to acquire Alexion for $39B - Drug Discovery and Development
AstraZeneca buys rare disease drugmaker Caelum in potential $500 mln deal | Reuters
Handok's 2023 turnover to drop sharply as AZ retrieves sales rights < Pharma < Article - KBR
Medicines | Alexion
How pharmaceutical company Alexion set the price of the world's most expensive drug | CBC News
MDA Celebrates FDA Approval of Alexion's Ultomiris for Treatment of gMG
